Huirong Ding
Impact in
-
- Cancer-related molecular mechanisms research
- MicroRNA in disease regulation
-
- Cancer Immunotherapy and Biomarkers
Papers in
- Oncology 10
- CAR-T cell therapy research 3
- Cancer-related Molecular Pathways 3
- Cancer Immunotherapy and Biomarkers 2
-
- Ubiquitin and proteasome pathways 4
- Co-authors
- Zheming Lu (5 shared papers)Yong Li (2 shared papers)Tao Ning (2 shared papers)Xiaojing Cheng (3 shared papers)Zheng Li (1 shared paper)Yaqi Pan (1 shared paper)Ke Yang (1 shared paper)Hongchao Xiong (1 shared paper)
- Journals
- Spectrochimica Acta Part A Molecular and Biomolecular Spectroscopy (2 papers)Cell Death and Disease (1 paper)Frontiers in Immunology (1 paper)BMC Cancer (1 paper)DNA and Cell Biology (1 paper)
- Partner nations
- ChinaEthiopiaUnited States
In The Last Decade
Huirong Ding
22 papers receiving 375 citations
Peers
Comparison fields: 5 of 76
- Cancer Research 77
- Oncology 110
- Hematology 44
- Pathology and Forensic Medicine 51
- Immunology 57
Countries citing papers authored by Huirong Ding
This map shows the geographic impact of Huirong Ding's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Huirong Ding with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Huirong Ding more than expected).
Fields of papers citing papers by Huirong Ding
This network shows the impact of papers produced by Huirong Ding. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Huirong Ding. The network helps show where Huirong Ding may publish in the future.
Co-authors
The 25 scholars most cited alongside Huirong Ding, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 23 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2008 | 58 | |
| 2 | 2020 | 55 | |
| 3 | 2018 | 49 | |
| 4 | 2019 | 40 | |
| 5 | 2018 | 33 | |
| 6 | 2011 | 31 | |
| 7 | 2012 | 22 | |
| 8 | 2022 | 18 | |
| 9 | 2014 | 13 | |
| 10 | 2014 | 13 | |
| 11 | 2013 | 12 | |
| 12 | 2023 | 5 | |
| 13 | 2022 | 5 | |
| 14 | 2022 | 4 | |
| 15 | Plasma CAMK2A predicts chemotherapy resistance in metastatic triple negative breast cancer. | 2018 | 4 |
| 16 | 2019 | 3 | |
| 17 | 2018 | 3 | |
| 18 | 2017 | 2 | |
| 19 | 2022 | 2 | |
| 20 | 2020 | 2 |
About Huirong Ding
Huirong Ding is a scholar working on Oncology, Molecular Biology, Pathology and Forensic Medicine, Immunology and Cancer Research, having authored 23 papers that have together received 376 indexed citations. Recurring topics across this work include Lymphoma Diagnosis and Treatment (5 papers), Ubiquitin and proteasome pathways (4 papers), MicroRNA in disease regulation (3 papers), CAR-T cell therapy research (3 papers), Cancer-related Molecular Pathways (3 papers), Monoclonal and Polyclonal Antibodies Research (3 papers), Immune Cell Function and Interaction (2 papers) and Cancer Immunotherapy and Biomarkers (2 papers). The work is most often cited by research in Cancer Research (77 citations), Oncology (110 citations), Hematology (44 citations), Pathology and Forensic Medicine (51 citations) and Immunology (57 citations). Huirong Ding has collaborated with scholars based in China, Ethiopia and United States. Frequent co-authors include Zheming Lu, Yong Li, Tao Ning, Xiaojing Cheng, Zheng Li, Yaqi Pan, Ke Yang, Hongchao Xiong, Wenlong Zhang and Miao Yu. Their work appears in journals such as Spectrochimica Acta Part A Molecular and Biomolecular Spectroscopy, Cell Death and Disease, Frontiers in Immunology, BMC Cancer and DNA and Cell Biology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.